Abstract | Radical radiotherapy for prostate cancer offers excellent long-term outcomes for patients with high-risk disease. The increased risk of pelvic nodal involvement in this cohort has led to the development of whole-pelvis radiotherapy (WPRT) with a prostate boost. However, the use of WPRT remains controversial. Data are mixed, but advanced radiotherapy techniques enable delivery of increased radiation to pelvic nodes with acceptable levels of toxicity. Contemporary imaging modalities with increased sensitivity for detecting subclinical lymph node disease will facilitate selection of patients most likely to benefit from WPRT. Using such modalities for image guidance of advanced radiotherapy techniques could also permit highdose delivery to nodes outside the conventional Radiation Therapy Oncology Group volumes, where magnetic resonance lymphography and single-photon-emission CT imaging have mapped a high frequency of microscopic disease. With increased toxicity a concern, an alternative to WPRT would be selective irradiation of target nodal groups most likely to harbour occult disease. New image-based 'big data' mining techniques enable the large-scale comparison of incidental dose distributions of thousands of patients treated in the past. By using novel computing methods and artificial intelligence, high-risk regions can be identified and used to optimize WPRT through refined knowledge of the likely location of subclinical disease.
. Radical radiotherapy for prostate cancer is associated with excellent long-term outcomes for patients with high-risk disease 3, 4 , but its efficacy can be limited by the presence of occult lymph node metastases outside of the radiation field in this patient cohort 5 . Whole pelvis radiotherapy (WPRT) is one method of improving outcomes in these patients; however, the benefit of WPRT in high-risk prostate cancer has long been a subject of contention. Two large randomized controlled trials comparing WPRT with prostate-only radiotherapy (PORT) reported negative results 6, 7 ; however, these trials were limited by the low radiation doses delivered, inclusion of patients at too low a risk of lymph node involvement (LNI) and suboptimal field size definition. Furthermore, retrospective evidence is mixed, with most series evaluating relatively small patient numbers. However, new prospective data are now emerging in favour of nodal irradiation 8 , suggesting that the time is right to re-open the debate surrounding WPRT. Furthermore, with the advent of intensity-modulated radiotherapy (IMRT), the incidental dose delivered to some pelvic nodal basins is much lower 9 . Prophylactic nodal irradiation is, therefore, likely to become increasingly relevant in the modern radiotherapy era with the more widespread use of progressively more conformal techniques 10 .
In this Review, we discuss WPRT in the exciting new age of contemporary imaging modalities, advanced image-guided radiotherapy and innovative image-based data mining and modelling techniques, all of which have the potential to substantially improve clinical outcomes in men with high-risk prostate cancer with nodal involvement.
Elective pelvic lymph node irradiation Rationale
The clinical factors used to define high-risk prostate cancer -baseline serum PSA level, tumour stage and Gleason score -are predictive of extracapsular spread, lymph node metastases and clinical outcomes in localized disease 11 . The first schema of risk stratification combining all three of these variables was proposed
Intensity-modulated radiotherapy
An advanced form of 3D radiotherapy that uses multiple narrow radiation beams of differing intensities aimed at the tumour from many angles to enable precise conformation of dose to the target.
New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer in 1998 by D' Amico and colleagues 12 , who used a primary end point of PSA failure -defined as three consecutive rising PSA values each obtained at least 3 months apartto retrospectively evaluate outcomes of >1,800 patients who underwent radical prostatectomy or radical radiotherapy for prostate cancer. They defined high-risk prostate cancer as one or more of the following: serum PSA ≥20 ng/ml, clinical T stage ≥T2c and Gleason score of ≥8 (ref. 12 ). The benefits of escalated radiation doses [13] [14] [15] and combined external beam radiotherapy (EBRT) plus extended androgen deprivation therapy (ADT) of 2-3 years' duration [16] [17] [18] in terms of biochemical progression-free survival (bPFS) have clearly been demonstrated in this high-risk, poor-prognosis group, although only ADT has been shown to confer an overall survival advantage [16] [17] [18] .The efficacy of dose-escalated EBRT to the prostate alone in patients with high-risk disease might be limited by the increased likelihood of occult lymph node metastases in pelvic lymph nodes outside of the radiation field 5 . Thus, the use of WPRT to target nodal micrometastatic disease, thereby eliminating routes of tumour spread and potentially improving outcomes in high-risk disease, has a biologically sound rationale. In the mid-1990s, Roach and colleagues developed an equation to approximate the likelihood of pelvic lymph node metastases commonly consulted by clinicians: LNI probability (%) = (2/3) baseline serum PSA + [(Gleason -6) x 10] 19 . Although no consensus has been reached, the authors recommend consideration of elective pelvic nodal irradiation in all patients with an LNI risk of >15%.
Surgical evidence
The results of two systematic reviews of radical prostatectomy 20, 21 have shown that an extended pelvic lymph node dissection (ePLND), to include removal of obturator, external iliac, internal iliac and hypogastric with or without presacral and common iliac nodes, improves the detection of nodal metastases compared with a limited procedure in which only the obturator nodes are removed, with or without external iliac nodes. Moreover, in patients with limited pelvic LNI, the removal of an increased total number of lymph nodes might be associated with improvements in survival, possibly attributable to the elimination of micrometastatic disease in these nodal regions 20, 21 . Thus, ePLND currently remains the most sensitive and specific nodal staging procedure in prostate cancer. Based on a review of a number of modern ePLND series, microscopic lymph node metastases will be present in 30-40% of patients with high-risk disease 22 . This proportion is well above the typical threshold for elective treatment of the regional lymphatics in other tumour sites, such as head-and-neck, gynaecological and rectal cancers, in which prophylactic irradiation of atrisk lymph nodes is the recognized standard of care [23] [24] [25] . However, despite this evidence, the value of elective pelvic nodal irradiation in men with high-risk prostate cancer remains controversial.
Retrospective series
Contemporary retrospective studies evaluating the benefits of WPRT over external beam PORT in patients with high-risk prostate cancer have produced conflicting results [26] [27] [28] [29] [30] [31] [32] [33] (TAble 1) .
A 2009 retrospective study included 277 patients with a Roach formula-defined risk of lymph node meta stases of ≥15% who had been treated with either PORT or WPRT 26 . Although patients in the WPRT arm had more advanced disease at presentation, 4-year biochemical recurrence-free survival (BRFS) was significantly better in this group than in those treated with PORT (86.3% versus 69.4%; P = 0.02). However, the improved BRFS came at the expense of an increase in acute gastrointestinal toxic effects, although no difference in late gastrointestinal sequelae was observed. In a smaller study from 2011, a total of 72 patients who had received either PORT or WPRT were grouped according to their risk of LNI as defined by the Roach formula using incremental values of 15%, 20%, 25% and 30% 27 to evaluate a potential threshold value for deriving benefit from nodal irradiation. After a 4-year follow-up period, no difference in biochemical recurrence rates was observed between the two arms across the entire study population. However, in the highest-risk cohort (LNI risk ≥30%), WPRT significantly improved 4-year BRFS from 70% to 88% (P = 0.03) with no demonstrable increase in associated toxicity. These data are in contrast to previous results of two retrospective analyses on 201 patients with a Roach formula-estimated risk of LNI of ≥15% treated with either WPRT or PORT 28 . Overall, WPRT improved 5-year BRFS from 24% to 48% (P < 0.001), but a subgroup analysis showed this improvement to no longer be statistically significant in the highest risk patients (LNI risk ≥35%); median BRFS of 27.2 months for those receiving WPRT and 20.8 months for those receiving PORT 29 . Although the number of patients in this specific cohort was small (n = 71), those patients at such a high risk could conceivably already have distant occult metastasis at presentation and would, therefore, lose the benefit of WPRT.
In 2015, data from the National Cancer Database (NCDB) were used to report the largest comparative retrospective analysis of PORT versus WPRT in the contemporary dose-escalated era 30 . A total of 14,817 patients with node-negative, high-risk prostate cancer were included in the study, 51% of whom received WPRT
Key points
• Prophylactic pelvic nodal irradiation in patients with high-risk prostate cancer might improve clinical outcomes.
• Negative results in clinical trials to date might be attributable to subtherapeutic radiation doses, inappropriate patient selection and suboptimal field size delineation.
• Conformal radiotherapy techniques reduce incidental pelvic lymph node dose, increasing the potential utility of whole pelvis radiotherapy (WPRT) in the modern intensity-modulated radiotherapy era.
• Contemporary imaging modalities with high sensitivity for the detection of occult lymph node metastases will improve patient selection for WPRT and guide appropriate target volume definition.
• Advanced radiotherapy techniques will permit dose escalation to minimally positive nodal regions, both inside and outside of the standard Radiation Therapy oncology Group target volumes.
• large-scale image-based data mining raises the possibility of selective irradiation of statistically identified high-risk nodal groups to improve the therapeutic ratio in WPRT.
Image-guided radiotherapy
The process of imaging during radiotherapy to ensure accuracy of treatment delivery and adherence to the actual radiation plan.
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and 49% of whom received PORT. No overall survival benefit was seen at 7 years with the addition of elective pelvic nodal irradiation using multivariate (72.0% (WPRT) versus 73.2% (PORT); P = 0.1) and propensity score-matched analyses (71.8% versus 72.9%; P = 0.141). This equivalence was maintained in patients receiving high-dose radiotherapy of 78-81 Gy and in those receiving EBRT in combination with a brachytherapy boost 30 . However, broad database analysis such as this has its limitations. First, the patients receiving WPRT had worse clinical prognostic factors at presentation, which was evident in the univariate analysis in which WPRT was associated with worse overall survival. The presence of such negative confounding factors might mask the benefit of WPRT, although the same results were produced with the propensity scorematched analysis, which attempted to eliminate this bias. Second, although the NCDB provides information on the receipt of ADT, it does not give details of the duration of treatment. As long-term ADT is known to affect clinical outcomes in patients with high-risk disease, this might be a confounding factor that is unaccounted for by propensity score-matched analyses. Third, patients were assigned to a treatment group defined solely by coding data ("prostate and pelvis" versus "prostate"). With no definitive information available as to the actual field sizes, target volumes and definition of WPRT could have been variable across the population. Some patients assigned to the WPRT arm might, therefore, not have received appropriate coverage of the pelvic nodes. Finally, the primary outcome of the analysis was overall survival. No information is available regarding important clinical parameters such as disease-specific survival, biochemical relapse, local control or distant metastasis, all of which could be influenced by WPRT.
Prospective data
Randomized controlled trials. Two contemporary prospective randomized controlled trials have taken place comparing PORT with WPRT in men with intermediaterisk and high-risk prostate cancer 6, 7 . Radiation Therapy Oncology Group (RTOG) 94-13 investigated the effects of WPRT in 1,323 men with a risk of LNI ≥15%, as predicted by the Roach formula. The study used a 2 × 2 factorial design intended to investigate both the benefit of WPRT and the timing of ADT 6 . Patients were assigned to one of four arms: WPRT + neoadjuvant ADT (NHT), WPRT + adjuvant ADT (AHT), PORT + NHT, or PORT + AHT. At primary analysis after 4 years, WPRT significantly improved progression-free survival (PFS) compared with PORT (54% versus 47%; P = 0.022) and a substantial PFS benefit was seen for intermediate and high-risk patients who had received WPRT + NHT compared with the other three arms (63.9% versus 46.4% (PORT + NHT), 48.9% (WPRT + AHT) and 49.3% (PORT + AHT); P = 0.014) 6 . However, updated results published after a 7-year follow-up period showed that PFS was no longer different between the PORT and WPRT arms (P = 0.59) 34 . This change might be related to the longer follow-up duration itself -the definition of PFS in the study included death from all causes and it would be expected that with time, death from other events might predominate over prostate cancer-related deaths. Moreover, the dose to the prostate in this trial was only 70 Gy, which is now considered suboptimal in the treatment of high-risk disease. A substantial proportion of patients might, therefore, have had a local recurrence in the prostate resulting in biochemical failure and masking any benefit of WPRT. Finally, the authors reported an unforeseen sequence-dependent interaction between field size and the timing of ADT: WPRT + NHT was shown to be the most favourable treatment option and WPRT + AHT the least favourable 34 . This unexpected interaction complicated the analysis and meant that the study was no longer adequately powered to compare each of the four treatment arms against each other.
The Genitourinary Study Group 01 (GETUG-01) trial was a smaller study of 444 men with clinically nodenegative, localized (T1b-T3) prostate cancer rando mized to receive either WPRT or PORT 7 . Patients were included irrespective of their prognostic group and only 45% of the population had an LNI risk of ≥15%. No signi ficant difference was observed in 5-year PFS (66.0% (WPRT) versus 65.3% (PORT); P = 0.34) or overall survival (86.5% versus 88.3%; P = 0.62) between the two arms. However, the majority of the patients included in the study had a risk of occult pelvic lymph node metastases of <15%, which might have been too low a risk for them to derive benefit from WPRT. Furthermore, the WPRT field sizes were small, with the upper border placed at the level of S1-S2 (ref.
7
). In 2017, a large-scale mapping study evaluated the patterns of lymph node failure in 2,694 patients with localized disease treated with dose-escalated radiotherapy to the prostate alone 35 . In this study, 60 patients experienced their first failure in the pelvic lymph nodes. Of these, the common iliac region was involved in 55% of patients, including 10% who presented with isolated common iliac nodal disease. Patients with high-risk T3/T4 disease were shown to have a five-fold increase in the chance of a common iliac node failure. The study also demonstrated that with a superior WPRT field border placed at L5-S1, only 41.7% of patients with pelvic lymph node failure would have had complete coverage of all recurrences. This figure increases to a more acceptable 93.4% when the field is extended upwards to L4-L5. However, when the border is placed inferiorly at S1-S2, as was the case in the GETUG-01 study, the common iliac region is not covered at all and the figure reduces to 33.3% ( fig. 1) . Thus, nearly 70% of the patients in the WPRT arm of GETUG-01 might have received a dose to the superior pelvic nodal basins that was insufficient for the eradication of micrometastatic disease, muting any potential benefit of prophylactic WPRT. Indeed, all of the patients' 'whole pelvis' fields in GETUG-01 would actually have been encompassed in the prostate-only arm of RTOG 94-13 (ref.
6
).
National UK HDR brachytherapy database
In both of these randomized phase III trials 6, 7 , the cumula tive doses of 66-70 Gy delivered to the prostate would now be regarded as suboptimal in the context of modern dose-escalation series [13] [14] [15] . With inadequate treatment of the primary tumour and poor local control, the potential benefit of regional nodal irradiation might be lost. Interstitial brachytherapy has been successfully used as a means of intensifying local dose to the prostate. The sharp fall-off in dose associated with this technique combined with the dose heterogeneity across the brachytherapy volume can result in dose escalation to some areas of the gland of >140 Gy. Three prospective randomized trials [36] [37] [38] comparing EBRT alone with EBRT combined with a brachytherapy boost in localized prostate disease have all shown that combined modality treatment signi ficantly improves biochemical control across all risk groups. One trial used high dose rate (HDr) brachytherapy 36 and the other used a permanent low-dose rate (LDR) iodine-125 seed implant 37, 38 . In all studies, ≥50% of the patients recruited had high-risk disease. In ASCENDE-RT, the larger of the two LDR trials, 398 patients were randomly assigned to receive WPRT 46 Gy in 23 fractions and either an iodine-125 LDR boost (115 Gy) or an EBRT prostate boost of 32 Gy in 16 fractions 37 . At 9 years, patients in the brachytherapy arm had improved BRFS of 83% compared with 62% for those receiving an EBRT boost (P < 0.001). Hoskin and colleagues report a similar bene fit in biochemical control when using HDR brachytherapy 36 . In this trial, 218 patients were recruited and treated with either 55 Gy in 20 fractions of EBRT to the prostate or 37.5 Gy in 15 fractions of EBRT to the prostate plus a HDR brachytherapy boost of 17 Gy in two fractions. BRFS at 7 years was 66% versus 48% (P = 0.04) in favour of the combined modality arm. With its unique ability to deliver extremely high intraprostatic doses and optimize local control, treatment with brachytherapy in combination with EBRT could be more likely to uncover the potential benefit of prophylactic pelvic nodal irradiation.
In 2018, data were reported from a prospective national UK database evaluating a standard protocol arising from a national consensus meeting delivering EBRT in combination with a single dose of 15-Gy HDR brachytherapy 8 . Two external beam schedules were permitted: 46 Gy in 23 fractions of WPRT or 37.5 Gy in 15 fractions of PORT preselected by each of the nine participating centres in the UK. In total, 812 patients with intermediate-risk or high-risk prostate cancer were recruited; 401 patients received whole pelvis radiotherapy (WPRT) and the remaining 411 received PORT. WPRT significantly improved 5-year bPFS (89% versus 81%; P = 0.007) with no increase in late radiation toxicity. The bPFS benefit was most apparent in the Percentages show the proportion of patients who would have had complete coverage of all pelvic nodal recurrences if the superior border of the whole pelvis radiotherapy field were placed at S1/S2, L5/S1 and L4/L5. Adapted with permission from ref.
35
, Elsevier.
High-dose rate (HDR) brachytherapy
A type of brachytherapy used in prostate cancer whereby a radioactive source is dispensed via a number of temporary catheters placed transperineally into the prostate to deliver radiation at a rapid rate of >12 gy/h.
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high-risk cohort (84% versus 77%; P = 0.001 ( fig. 2 ).
Although non-randomized, this is the only prospective study to date to evaluate the effect of WPRT when given in combination with interstitial brachytherapy to maximize dose escalation to the prostate. With optimization of local control, it suggests that prophylactic pelvic nodal irradiation in appropriately selected patients could be of clinical benefit.
Toxicity of pelvic nodal irradiation
With the use of IMRT and conformal planning, prostate radiotherapy is generally well tolerated and patients experience minimal treatment-related morbidity. Most retrospective series describe some increase in acute toxicity with WPRT; gastrointestinal adverse-effects are more common than genitourinary symptoms 26, 39 . Toxicity data from the National UK HDR brachytherapy database also showed WPRT to increase acute genitourinary toxicity but with no effect on late radiation morbidity 8 . By contrast, in the updated analysis of RTOG 94-13 (ref.
34
), a significant increase in late gastrointestinal toxicity ≥G3 was observed in the WPRT + NHT arm (5%) compared with 1% in the PORT + NHT arm and 2% in both the WPRT + AHT and PORT + AHT arms (P = 0.002). The relationship between field size and toxicity was corroborated by the subgroup analysis comparing whole-pelvis (WP), mini-pelvis (MP) and prostate-only (PO) fields, in which the incidence of severe late gastrointestinal sequelae correlated with increasing treated volume 40 .
As a major organ-at-risk in pelvic radiotherapy, the determination of appropriate dosimetric constraints to the bowel is an important issue to minimize intestinal toxicity, but it remains underinvestigated and, until recently, has been limited to retrospective analyses [41] [42] [43] . In the largest of these retrospective studies, the dosimetric planning and clinical data of 191 patients with localized prostate cancer who underwent WPRT with radical or adjuvant and/or salvage intent were evaluated 41 . The volume of bowel receiving 40-50 Gy (V40-V50 Gy) was found to be a significant dosimetric predictor of acute bowel toxicity, an effect corroborated by smaller studies 42, 43 . In 2017, the results of the first prospective study to evaluate dosimetric and clinical predictors of patient-reported intestinal toxicity in those treated with WPRT for prostate cancer were described 44 . The study enrolled 206 patients across six institutions, for whom complete dosimetric data were available. Intestinal symptoms were assessed using the Inflammatory Bowel Disease Questionnaire between baseline, midpoints and end points of radiotherapy. An association was shown between absolute dosevolume histogram (DVH) shape and patient-reported loose stools. Consistent with retrospective data [41] [42] [43] , the volume of bowel receiving higher radiation doses of 40-50 Gy was more predictive of loose stools than the volume receiving lower doses of 5-30 Gy, suggesting that constraining the overall bowel loop DVH might reduce the risk of this intestinal toxic effect. Importantly, on multivariate analysis, increasing age was also shown to be an independent protective factor, with a patient of 65 years at almost double the risk of loose stools in the acute setting than a patient of 75 years. As the authors suggest, this result is in line with the individual radiation-induced inflammatory reaction, which would be presumed stronger in younger patients 44 . Treatment-related morbidity and its underlying causative factors are, therefore, important aspects to consider when selecting patients for elective prophylactic nodal irradiation in primary prostate cancer, especially when its true benefit in terms of clinical outcome remains to be determined. WPRT for postoperative recurrence A number of retrospective studies have shown a benefit in bPFS derived from additional irradiation of the whole pelvis compared with radiation to the prostate bed only (PBRT) in patients with biochemical recurrence following prostatectomy, although these studies were limited to patients with either high-risk disease 45, 46 or an elevated PSA level (≥0.4 ng/ml) before salvage radiotherapy 47 . The results of these series were supported by a 2018 multi-institutional retrospective analysis of >1,800 patients who underwent salvage radiotherapy postprostatectomy 48 . At a median follow-up duration of 51 months after treatment, WPRT was associated with a 13% absolute improvement in freedom from biochemical failure compared with PBRT, increasing to 16% in the subset of patients with Gleason score 8-10 disease.
The RTOG 0534 SPPORT trial was the first prospective randomized controlled trial to evaluate the benefit of WPRT in the salvage setting 49 . From 2008 to 2015, a total of 1,792 men with persistently detectable or rising PSA levels postprostatectomy were enrolled at centres across the USA, Canada and Israel. Patients were randomly assigned to receive PBRT alone, PBRT + short-term (4-6 months) ADT, or WPRT and PBRT + short-term ADT. The primary end point was free dom from disease progression (FFP) at 5 years after treat ment and failure was defined as a PSA rise of 2 ng/ml above the nadir value postradiotherapy, clinical progression or death from any cause 50 . The results of an interim analysis conducted when 1,191 patients had been followed up for 5 years showed FFP rates to be 71.7% for PBRT alone, 82.7% for PBRT + ADT and 89.1% for WPRT, PBRT + ADT (P < 0.0001). Moreover, for all eligible patients followed up for 8 years, rates of distant meta stases were also signi ficantly lower for triple therapy than for PBRT alone (HR 0.52, 95% CI 0.32-0.85) and trended towards a benefit compared with PBRT + ADT (HR 0.64, 95% CI 0.39-1.06). With respect to toxicity, gastro intestinal adverse events of grade ≥2 were higher in patients treated with additional WPRT (6.9% versus 2.0% for PBRT alone) as were blood and bone marrow adverse effects of grade ≥2 (5.1% versus 2.3%) and grade ≥3 (2.6% versus 0.5%) 50 . Additional follow-up studies are clearly required, with particular focus on the magnitude of difference between the experimental arms in order to isolate the benefit of WPRT from ADT and also work to identify patients of reduced risk who might not require such intense treatment. However, the early observation of diffe rences in distant metastases emphasizes the strength of the reported effect and suggests that in selected patients, the benefit of pelvic nodal irradiation in the salvage radio therapy setting might be upheld in the long term. In light of this new evidence, combining irradiation of the prostate bed and pelvic nodes with 4-6 months of ADT should now be considered more seriously in patients with postoperative biochemical recurrence than is current practice.
Incidental pelvic lymph node irradiation
Elective irradiation of at-risk regional lymph nodes is common in a number of solid tumours, but it is no longer used in the radiotherapy of lung cancer 51 or lymphoma 52 .
In lung cancer, the incidental dose to the mediastinum arising from treatment of the primary tumour in close proximity is thought to be sufficient to treat the local lymph nodes, effectively equating to prophylactic irradiation 51 . The same might be true for prostate cancer and pelvic lymph nodes, particularly with the use of conventional radiotherapy techniques, which deliver radiation in fields that are larger and less conformal than modern approaches. To test this hypothesis, Heemsbergen and colleagues 53 evaluated clinical failure rates of 164 high-risk prostate cancer patients treated within a randomized controlled trial in which the original aim was to compare toxicity levels in patients treated with conventional rectangular fields compared with those treated with modern 3D conformal radiotherapy. At a follow-up duration of 34 months, significantly fewer clinical failures were observed in patients treated with rectangular fields compared with conformal fields (9 versus 24; P = 0.012) and dosimetric analysis showed that, on average, an increased incidental dose was delivered to pelvic nodal regions in the rectangular arm 54 . These data support the notion that incidental irradiation to nodal areas and the resulting treatment of subclinical disease potentially residing there might be advantageous, particularly in those patients who are at high risk of occult nodal metastases. In the two prospective randomized trials to date comparing WPRT with PORT in localized prostate cancer 6, 7 , prostate-only radiation was delivered using either conventional unblocked square-field techniques 6, 7 or four-field 3D plans with block or multileaf collimator shielding 7 . The use of these older, less conformal techniques in these trials could mean that the incidental radiation dose delivered in the PORT arms to the pelvic lymph nodes might have been sufficient to eradicate microscopic disease, thereby negating any additional benefit of WPRT and contributing to the negative results observed.
This concept is further supported by an elegant dosimetric study in which the plans of 20 patients with highrisk prostate cancer treated with IMRT to the prostate alone were evaluated 9 . Re-planning was carried out for all patients using IMRT, 3D conformal (3DCRT) and 2D conventional planning techniques with additional delineation of the individual pelvic nodal regions. Dose-volume parameters to each nodal basin were then calculated for each of the three planning techniques in all patients. The obturator region was shown to receive the highest dose across all three techniques; the mean obturator dose received was 44 Gy, 29 Gy and 22 Gy for 2D, 3DCRT and IMRT, respectively. Corresponding D33% values were 64 Gy, 39 Gy and 37 Gy, respectively. The dose required to eliminate microscopic meta stases in prostate cancer has not been established. RTOG 94-13 and GETUG-01 used WPRT doses of 50.4 Gy at 1.8 Gy per fraction and 46 Gy in 2-Gy fraction sizes, respectively, with a pelvic recurrence rate of only 1.3% at 4 years in RTOG 94-13 (ref. 6 ) and a combined local, regional and distant recurrence rate of <8% at 5 years reported in GETUG-01 (ref. 7 ). An incidental dose of around 44 Gy as achieved with 2D conventional planning techniques 9 could, therefore, conceivably be adequate to treat occult lymph node metastases, particularly with a 3D conformal radiotherapy A type of radiotherapy that uses special imaging modalities to define the 3D shape of the tumour and computercontrolled planning techniques to conform the radiation beams to the target.
D33%
Mean radiation dose delivered to 33% of a defined target volume typically derived from a dose-volume histogram.
www.nature.com/nrurol potential additional radiosensitizing effect of androgen suppression. Murine studies have shown NHT to substantially enhance the ability of radiotherapy to eradicate hormone-sensitive cancers in vivo, with the total radiation dose needed to control 50% of the tumour falling from 89 Gy in intact mice to 60.3 Gy in orchidectomized mice 55 . However, even in combination with ADT, the much lower incidental pelvic nodal doses of less than 25 Gy achieved using IMRT 9 are unlikely to influence micrometastatic disease and, as such, prophylactic pelvic nodal irradiation might become increasingly relevant in the modern IMRT era.
Predicting the risk of lymph node involvement The current body of evidence demonstrates that the accurate identification of those men who harbour occult regional nodal disease and appropriate patient selection are critical to effecting the benefit of prophylactic pelvic irradiation for men with prostate cancer. Ideally, only patients with microscopic or small-volume macroscopic lymph node disease should be candidates for WPRT 56 . Surgical lymph node dissection would be the most precise method of identifying this cohort, but this is an invasive technique with limited sensitivity, as many patients have microscopic nodal disease outside the standard dissection template 57 . Thus, alternative methods to identify and select patients are required. . From these data, the previously described Roach formula was derived to stratify patients and estimate their likelihood of developing lymph node metastases 19 . As this formula has not been updated since its origin in 1994, downward stage migration and earlier detection as a result of more widespread use of PSA testing might decrease the risk of subclinical LNI for the stated Gleason scores and PSA values, which could ultimately lead to an overestimation of pelvic lymph node risk using the Roach equation 59 . However, data for the original Partin tables were derived from radical prostatectomy studies using standard lymphadenectomy 58 , but the results of a number of modern extended lymph node dissection (eLND) series have consistently shown that 40-50% of pelvic lymph node metastases occur outside of the standard dissection template 22, [60] [61] [62] [63] . The Roach formula has been shown to remain accurate when validated in contemporary prostate cancer patient cohorts treated with extended lymphadenectomy, with the calibration actually showing a minor underestimation of the risk of LNI in high-risk patients 64 . Moreover, given that a further 5-10% of lymph node metastases might reside outside even the eLND dissection borders 65, 66 and that up to 40% of microscopic LNI can be missed by standard pathological examination techniques 67,68 the true estimate of pelvic lymph node metastases in high-risk disease could conceivably be greater than that predicted by the Roach formula.
Predictive nomograms
Using data derived from eLND studies, Briganti and colleagues have since developed an updated nomogram to predict the risk of LNI in node-negative patients with prostate cancer 69 . In addition to stage, Gleason score and PSA, this model also incorporates the percentage of positive cores on biopsy, a known strong prognostic indicator 70 , and has been externally validated in contemporary patient cohorts 71, 72 . On direct comparison of accuracy in predicting LNI risk, the Briganti nomogram attained a receiver operating characteristic (ROC) curve of 0.88 compared with 0.84 achieved with the Partin tables (ref.
73
). Although the difference was not statistically significant (P > 0.2), the small sample size (n = 173) made the study underpowered to detect such a difference. The 4% gain in more accurate discernment using the Briganti nomogram can be considered clinically significant and merits its preferred use 73 .
Imaging modalities
Despite the utility of predictive nomograms, the gold standard in non-invasive pretreatment nodal staging would be an imaging technique able to accurately detect the presence of clinically occult pelvic lymph node metastases, but conventional cross-sectional imaging modalities are limited in this regard. CT and MRI rely primarily on anatomical features of lymph nodes, such as size and shape, to determine metastatic infiltration, with a threshold of >1.0 cm in the short axis typically defined as pathological 74 . However, a histological study demonstrated that over half of metastatic pelvic lymph nodes in men with prostate cancer might be <1 cm across 75 . The results of a pooled meta-analysis showed the sensitivity of CT and MRI in detecting metastatic nodes of any size to be only 42% and 39% respectively; both techniques had a specificity of 82% 76 . Given the limited value of standard imaging in nodal staging, a number of advanced modalities including choline positron emission tomography (PET) 77 , prostate-specific membrane antigen (PSMA)-targeted PET 78 and high-resolution magnetic resonance lymphography (MRL) 79, 80 have been developed and evaluated in this respect.
Choline-PET.
Choline is a molecule taken up by tumour cells following phosphorylation by choline kinase, an enzyme appreciably upregulated in prostate cancer 81 . Improved detection of pelvic lymph node metastasis has been shown using 84, 85 , and a meta-analysis showed that choline-PET has a pooled sensitivity of 49.2% and specificity of 95% for the detection of metastatic lymph node disease 86 . This sensitivity rate is not that much higher than the 42% and 39% reported with conventional imaging modalities of CT and MRI, respectively 76 , and the routine use of choline-PET for staging of nodal metastases in prostate cancer is, therefore, not currently recommended 87 .
PSMA-PET.
PSMA is a type II transmembrane protein expressed in benign prostate and other tissues such as the salivary glands and jejunum 88 . However, PSMA is overexpressed at levels of up to 1,000-fold higher in prostate adenocarcinoma cells, and its expression increases with Ga-PSMA-PET imaging before prostatectomy and pelvic lymph node dissection showed that 68 Ga-PSMA-PET had superior accuracy in the detection of nodal metastases compared with morphological imaging (CT and MRI) with sensitivity, specificity and accuracy of 65.9%, 98.8% and 88.5% versus 43.9%, 85.4% and 72.3%, respectively; P = 0.002 (ref.
93
). These results are consistent with a smaller prospective evaluation of 68 Ga-PSMA-PET/CT for preoperative lymph node staging, which also reported a specificity of 98% and sensitivity of 56% 94 . However, lower detection rates have also been reported in the literature, with the acknowledgement that the sensitivity of 68 Ga-PSMA-PET is influenced by lymph node size 95 . In a retrospective study comparing preoperative 68 Ga-PSMA-PET/CT lymph node detection rates with histological findings after radical prostatectomy, the median size of PSMA-PET-detected versus PSMA-PET-undetected lymph nodes was 13.6 mm versus 4.3 mm (P < 0.05) 95 . Nevertheless, overall, 68 Ga-PSMA-PET has potential as an accurate imaging modality for the early detection of pelvic nodal metastasis in primary high-risk prostate cancer, particularly when combined with MRI sequencing, which should improve spatial resolution. A prospective study evaluating 122 patients with 68 Ga-PSMA-PET/MRI reported an accuracy rate of 93% for nodal staging using this hybrid imaging technique 96 . However, the clinical data are currently limited and more robust prospective evidence is required to fully evaluate this potential.
Magnetic resonance lymphography.
Of all the contemporary imaging modalities, MRL has shown the most promise in the initial lymph node staging of prostate cancer. This technique uses an intravenous contrast agent (ferumoxtran-10) consisting of ultra-small super paramagnetic iron oxide (USPIO) particles, which upon injection are transported to normal lymph node tissue and phagocytosed by resident macrophages 97 . The iron oxide disrupts the magnetic field used for imaging and causes signal loss such that, on T2-weighted MRI performed 24-36 h after contrast medium infusion, normal lymph nodes appear black 98 . However, metastatic lymph nodes maintain their signal intensity as fewer macrophages are present, resulting in reduced uptake of USPIO particles 99 . Thus, metastatic nodes can be accurately localized without reliance on nodal size 79 . Harisinghani et al. 79 evaluated 80 patients with localized prostate cancer who underwent surgical lymph node resection or biopsy. All patients were examined with MRL before resection or biopsy and the imaging results correlated directly with the histological findings of the sampled lymph nodes. They showed the overall sensitivity and specificity of MRL to be 90.5% and 97.8%, respectively. These results have been corroborated in a large prospective Dutch multicentre trial in which 375 patients with intermediate-risk or high-risk prostate cancer were recruited from 11 centres in the Netherlands 80 . All patients were investigated with CT and MRL and subsequently underwent pelvic lymph node dissection or fine-needle aspiration. Similarly, imaging and histopathology findings were correlated. Sensitivity of MRL was 83% compared with 34% for CT (P < 0.05) and MRL negative predictive value was 96% versus 88% for CT (P < 0.05) 80 . The high sensitivity and negative predictive value for MRL seen in this study are particularly encouraging, suggesting that those patients whose MRL is negative might have a <4% chance of harbouring subclinical pelvic lymph node disease 80 . Moreover, MRL is an imaging modality with high spatial resolution, which facilitates the detection of occult metastases in small, non-pathologically enlarged lymph nodes at an earlier stage than other techniques such as PET/CT 100 , particularly when diffusion-weighted sequences are used in combination with USPIO 101, 102 . A cost-analysis study has also shown MRL to be more cost-effective as a nodal staging modality than pelvic lymph node dissection or CT, with potential savings when performing MRL instead of PLND or CT of €1,467 and €1,310, respectively 103 , thereby strengthening its potential as a routine investigation to improve decision support in high-risk prostate cancer.
Radiation dose and fractionation
IMRT describes an advanced radiotherapy technique that enables more conformal planning shaped to the planning target volume (PTV) with a sharper dose falloff beyond it 104 . Excess radiation to the surrounding organs-at-risk (OARs) is reduced, enabling higher doses to be delive red to the prostate without increasing concomitant toxi city 10 . Dose escalation to the prostate has repeatedly been shown in randomized trials to improve biochemical disease control [13] [14] [15] 105 and has now become routine in prostate radiotherapy. In the largest of these phase III dose escalation trials, Michalski et al. 106 have shown IMRT to significantly reduce gastrointestinal toxicity in this setting. They evaluated 748 patients randomized to the 79.2-Gy arm of the trial, 491 of whom were treated with 3DCRT and 257 with IMRT. At a 3-year follow-up point, patients in the 3DCRT arm had a cumulative incidence of late GI toxicity of grade 2 or greater of 22% compared with only 15.1% for patients in the IMRT arm (P = 0.039) 106 . Given the established benefits of prostate dose escalation, the notion that intensifying the dose to micrometastatic lymph node disease might also be required to improve clinical outcome in WPRT is biologically sound. However, to date, prophylactic nodal doses have been modest to avoid toxicity to the bowel, and such suboptimal treatment has possibly contributed to the lack of benefit seen with WPRT in randomized trials 7, 34 . With increased bowel sparing, IMRT now raises the possibility of dose escalation to the pelvic nodes. Furthermore, with parallel improvements in image-guided radiotherapy technologies, interest in hypofractionation -whereby highly conformal radiotherapy is delivered in larger daily www.nature.com/nrurol fractions of 2.5-10 Gy over a reduced time period -has increased 107, 108 . The underlying biological hypothesis for applying hypofractionation to prostate cancer is based upon its low α/β ratio and relatively slow proliferation rate of the tumour. This characteristic gives prostate cancer cells an increased ability to repair sublethal radiationinduced DNA damage, meaning that small increments in dose over long time periods might be suboptimal for local tumour control 109 . Data from the randomized, phase III CHHiP study, which evaluated >3,000 patients with predominantly low-to-intermediate-risk disease showed that a dose schedule of 60 Gy in 20 fractions had equivalent outcomes to conventional fractionation of 74 Gy in 37 fractions 110 and hypofractionation has since become the standard of care in the UK for this patient cohort.
A number of clinical studies have investigated pelvic nodal dose escalation in prostate radiotherapy using both conventional and hypofractionated regimens [111] [112] [113] [114] [115] [116] (TAble 2 ). All studies demonstrate the feasibility, tolerability and safety of pelvic dose escalation using advanced radiotherapy techniques, and only a small proportion of patients, ≤7% in any study, developed severe (grade 3-4) acute or late toxicity [111] [112] [113] [114] [115] [116] . The largest of these evaluated >440 patients with high-risk prostate cancer and was reported in 2017 (ref.
116
). In this single-centre, phase I/II trial, patients were sequentially assigned to be treated with [70] [71] [72] [73] [74] Gy to the prostate and dose-escalating pelvic lymph node doses of 50 Gy (cohort 1), 55 Gy (cohort 2) and 60 Gy (cohort 3) in 35-37 fractions. Two doseequivalent hypofractionated cohorts received 60 Gy to the prostate and 47 Gy to the pelvic lymph nodes in 20 fractions over 4 weeks (cohort 4) and 5 weeks (cohort 5). Late grade 3-4 bowel toxicity rates were 0%, 1.5% and 2.2% in conventionally fractionated cohorts 1-3, respectively. Corresponding rates in the hypofractionated cohorts (4 and 5) were 6.6% and 0.8%, respectively. Late grade 3-4 bladder toxicity rates were 4.2%, 2.9%, 2.2%, 1.6% and 1.2% for cohorts 1-5, respectively 116 . With the exception of cohort 4, these late toxicity rates were comparable with those of the CHHiP study 110 , in which IMRT was used to treat the prostate alone using similar hypofractionated and conventional schedules. Both acute and late gastrointestinal toxicity were increased in cohort 4, possibly owing to a consequential late side effect as extension of the overall treatment time from 4 to 5 weeks was shown to reduce grade 2 or greater gastrointestinal toxicity rates acutely (48% versus 66%) and at 2 years (12.2% versus 16.7%) 116 . Taken together, these data suggest that pelvic node dose escalation can be delivered safely using IMRT in the context of both hypofractionated and conventional regimes.
Modern imaging modalities have the potential to visualize micrometastatic lymph node disease 117 . As an alternative to dose escalation to all pelvic nodal regions, accurate imaging could enable high-dose delivery to positive nodes only, with prophylactic doses delivered to other nodal basins, thereby reducing the risk of toxic effects. In a study of 26 patients with intermediate-tohigh-risk primary or recurrent prostate cancer, choline-PET/CT imaging was used to detect the presence of pelvic nodal metastases, which were shown to be present in 20 patients 118 . These images formed the basis of radiotherapy plans, in which a median dose of 75.6 Gy was delivered to primary tumours, 66.6 Gy to PET-positive α/β ratio A parameter derived from linear quadratic doseresponse curves that determines the sensitivity of different types of tissue to radiation doses. NATuRe RevIeWS | UROlOGy lymph nodes and 45-50.4 Gy to elective nodal regions, all in 1.8-Gy fractions. In patients with recurrence, 60-66.6 Gy was delivered to the prostate bed. Three-year BRFS was 83% and 49% for those with primary and recurrent disease, respectively. No incidence of acute toxicity above grade 2 was observed. The majority of patients (84%) experienced either no or mild (grade 1) late toxicity. One instance of severe bladder shrinkage (grade 4) that required bladder removal and ileal conduit formation 2 years after PET/CT IMRT was reported. However, this effect was seen in a patient who had previously been treated with curative intent with permanent iodine-125 seed implantation and was managed on an individual basis having been fully informed of the risks of re-irradiation 118 .
In the salvage setting, PSMA-PET/CT-based radiotherapy was delivered to 129 patients with biochemical persistence or recurrence following radical prostatectomy 119 . Cumulatively, a median dose of 70 Gy (2-2.14 Gy per fraction) was delivered to local macroscopic disease, 66 Gy to the prostate bed (2 Gy per fraction), 61.6 Gy to PSMA-PET-positive lymph nodes (1.85-2.2 Gy per fraction) and 50.4 Gy to the remaining pelvic nodal regions (1.8 Gy per fraction). After a 20-month follow-up period, median PSA levels were 0.05 ng/ml in patients who had not received ADT and 0.07 ng/ml in those receiving ongoing ADT 119 . At the same time point, 89% of the total study population had a serum PSA concentration of ≤0.2 ng/ml, showing that PSMA-PET-based radiotherapy can be an effective local salvage treatment modality with the potential to defer long-term ADT or systemic therapy 119 . The feasibility of using MRL-guided radiotherapy has also been demonstrated in a planning study of primary high-risk prostate cancer patients with no enlarged pelvic nodes on CT but in whom MRL revealed pathological nodal disease 120 . The MRL-positive lymph nodes were identified and delineated on the planning CT to create a boost volume and an individualized elective target volume defined based on their location. Highly acceptable IMRT plans with respect to the prescribed dose to the planning target volume and dose constraints to the OARs were generated delivering, in 30 fractions, 72 Gy to the prostate, 60 Gy to MRL-positive lymph nodes and 42 Gy to the elective nodal volume 120 . In one patient, the dose constraint to the small bowel was exceeded, with 1.1 cc receiving >52 Gy, but this dose was deemed acceptable given the mobility of this organ and the likelihood that a different part of it would lie in this high-dose area each day 120 .
Taken together, these studies suggest that the further development of advanced imaging techniques and their more widespread clinical use could facilitate highly personalized image-based pelvic irradiation in prostate cancer, potentially reducing treatment-related toxicity while improving clinical outcomes.
Planning target volumes and node mapping
The widespread adoption of modern, highly conformal IMRT techniques to deliver WPRT, raises the possibility of an increased risk of spatially missing crucial lymphnodal stations that needs to be addressed. With older conventional and 3DCRT approaches, once the craniocaudal, anterior-posterior and lateral borders of the irradiation field were set, all of the structures within this defined area were irradiated. However, when using IMRT, the radiation oncologist is required to precisely delineate not only the OARs but also the tumour targets. Correct knowledge of the location of the pelvic nodes at risk of micrometastatic disease and their accurate delineation is, therefore, crucial to the delivery of effective prophylactic WPRT.
Studies have shown significant discrepancies between expert genitourinary radiation oncologists in the delineation of the pelvic nodal clinical target volume (CTV) for radical prostate radiotherapy 121 , demonstrating the need for a consensus-contouring guideline. Thus, the RTOG target volumes for WPRT were subsequently developed 122 (box 1).
These guidelines were based primarily on data from eLNDs, prostatic lymphography and sentinel node studies 122 . However, conventional lymphography typically maps only the para-aortic, external and common iliac nodal areas 123 and the dissection template of eLND does not include the pararectal or para-aortic nodes 124 . Thus, data from these modalities will not evaluate all potential landing sites for prostate lymph node metastases.
Studies using modern imaging techniques such as MRL 125 and single photon emission CT (SPECT) 66 with increased sensitivity for the detection of micrometastatic nodal involvement have shown that a substantial number of prostate cancer patients have subclinical lymph node disease in regions outside the standard RTOG target volumes. A comprehensive 3D anatomical atlas of sentinel node distribution derived from SPECT imaging showed that, of the 61 patients evaluated, 40 had a sentinel node outside the conventionally irradiated pelvic volume 66 . Similar results were found in an MRL mapping study, which showed over half of MRLdetected positive lymph nodes to be outside the RTOG nodal target volume 125 . The most frequently reported aberrant sites outside of the target volume in this study were the proximal common iliac (30%), pararectal (25%) and para-aortic (18%) regions. These results were corroborated by a large-scale CT-based mapping study of >2,500 patients by Spratt and colleagues, in which the common iliac nodal basin was involved in 33 of the 60 patients presenting with their first failure in the pelvic lymph nodes alone. In the overall patient cohort of abdominal and pelvic first failures (n = 156), the para-aortic lymph nodes were most commonly involved (n = 80) 35 .
Box 1 | Clinical target volumes for pelvic nodal irradiation in prostate cancer

RTOG pelvic nodal volume
• Distal common iliac: Commence contouring at l5/S1 interspace • Presacral: Contour from S1 through to S3 • external iliac: Stop contouring at the top of the femoral heads • Internal iliac: Connect the internal and external contours on each slice • obturator: Stop contouring at the top of the pubic symphysis lymph node clinical target volumes include the vessels (artery and vein) plus a 7 mm radial margin edited of bowel, bladder and bone. RToG, Radiation Therapy oncology Group.
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As imaging modalities available for nodal staging become more advanced and considering the substantial proportion of patients likely to have out-of-field regional metastases, planning target volumes must also be reconsidered (fig. 3) . Ideally, standard volumes would be expanded to include all further encompassable nodal regions where micrometastases could land, but this approach would be at the risk of increased toxicity and might limit dose escalation to positive nodes. Alternatively, high-accuracy modern imaging modalities could be used to guide an individualized CTV for each patient with irradiation of standard nodal volumes and incorporation of additional lymph node regions only as radiologically indicated 56 . However, although they are more sensitive than conventional approaches, such imaging techniques might not detect all subclinical disease. An attractive alternative to avoiding both overtreatment and undertreatment would be dose escalation to involved nodes, with prophylactic irradiation of only those specific nodal groups most likely to harbour occult micrometastases. In this respect, image-based data mining in radiotherapy offers a novel and innovative method for the large-scale comparison of dose distributions of thousands of patients treated in the past where highrisk regions related to tumour control can be statistically localized and potentially used to optimize pelvic radiotherapy target volumes 126 .
Image-based data mining in radiotherapy The ultimate aim of radical radiotherapy is to provide a high dose of radiation to the target tumour while minimizing that received by the surrounding normal tissues. Dose-response relationships describe the correlation between radiation dose delivered to a defined anatomical construct and the likelihood of a specific clinical end point -usually clinical failure or toxicity -occurring. Thus, they provide integral information to clinicians attempting to optimize the balance between coverage of the CTV and exposure of OARs. Historically, doseresponse relationships have been based on data obtained from DVH analyses, whereby planned 3D dose distributions are amalgamated into a single dosimetric measure (for example, mean dose), which is then correlated with a clinical end point 127 . However, such DVH-based predictive models have limitations. First, they are unable to account for the spatial distribution of dose; although the dose delivered to the designated CTV is relatively uniform, the dose to the surrounding tissues can be highly heterogeneous depending on planning techniques, patient geometry and the location of the tumour 128 . Such subtle variations in subsidiary dose distributions might not be identified by whole organ DVHs, but they have potential to affect treatment outcomes both in terms of tumour control (where occult disease is important) and toxicity. Second, DVH analyses require delineation of all relevant structures, necessitating considerable time and personnel 129 . This significantly limits the number of patients and images that can be evaluated at any one time. Moreover, before DVH analyses can be performed, a hypothesis regarding the relationship between the specific regions delineated and clinical outcomes is required. Thus, DVH analyses do not lend themselves to exploratory studies.
Image-based data mining describes a novel and innovative method that can be used for the large-scale comparison of incidental dose distributions from patients treated in the past to create 'big data' models able to characterize previously unknown dose-response relationships 130 . Through the creation of dose-difference maps, voxel-by-voxel spatial analysis enables the dose at each voxel to be directly compared between patients without the need for any preceding anatomically based assumptions 126 . Suspicious regions can be localized and taken into consideration with clinical and biological parameters to formulate dose-response hypotheses; validation of these dose-response relationships can then provide evidence to assist radiotherapy planning by refining knowledge of the location of subclinical disease, for example, the presence of metastases in the pelvic nodal basins, and enable more cautious sparing of particular subregions of OARs.
Image-based data mining in prostate cancer Tumour control. In high-risk prostate cancer, the increased rates of early clinical failure after radiotherapy can be attributable to both subclinical extracapsular spread and occult metastases in the pelvic lymph nodes present at the time of treatment. Evaluation of largescale dose-response relationships for incidental dose delivered outside of the PTV might, therefore, provide useful information to predict localization of microscopic disease. In patients with high-risk disease, correlating incidental pelvic lymph node dose with clinical failure in large patient cohorts could provide evidence regarding the benefits of WPRT. In this respect, Witte et al. 129 performed a dose-mapping study in 352 patients to investigate whether incidental dose in regions outside of the prostate was associated with freedom from biochemical failure at 4 years after treatment. Patients had intermediate-risk or high-risk tumours and had received either 68 Gy or 78 Gy to the prostate and seminal vesicles as part of a dose-escalation trial 14 . Images were mapped onto a common template by defining anatomical points outside of the prostate located in the same position relative to its centre of mass. Dose-difference maps for patients with and without failure were created and a voxel-by-voxel t-test was performed on the difference between images. Points in the obturator and presacral nodal regions were identified, where a lower dose was associated with a higher risk of treatment failure 129 ( fig. 4) . These findings suggest that incidental intermediate radiation doses outside of the primary target might affect treatment outcome of patients at high risk of pelvic lymph node metastases through the eradication of microscopic disease in these regions. However, the study by Witte and colleagues has limitations that make it difficult to draw firm conclusions regarding the benefits of pelvic nodal irradiation based solely on its findings 129 . First, it was a point-based analysis, not an evaluation of the dose to whole volumes; had a nearby point been chosen, the dose levels might have been quite different, with average doses in the nodal region reported to vary greatly from 30 to 70 Gy. Thus, these point results cannot necessarily be considered representative of the dose to the nodal basin. Moreover, the obturator and presacral effects were not stable across disease stage and the association between dose at these points and clini cal outcome was lost in the multivariate analysis over the total group of patients 129 . As the authors note, therefore, this retrospective analysis is not one upon which decisions regarding WPRT could be made. However, it does demonstrate the extent of potential dose-response relationships outside the prostate PTV and serves as an informative exploratory study in identifying possible nodal regions as targets for high-dose irradiation.
To validate the results of this experimental analysis, Heemsbergen et al. carried out a further study investigating the failure rates of 164 patients with high-risk prostate cancer who were randomized to receive radio therapy Fig. 4 | Image-based data mining infrastructure. Based on an outcome database, imaging data (CT scan, dose grid and contours) are collected from the clinical treatment planning system. To compare dose distributions, data are spatially normalized to a template patient. At the data collation step, the difference between patients with or without biochemical recurrence at 48 months is calculated. To test significance, the clinical variables are randomized and the random observations are compared with the actual observation (permutation testing). Examples of the resulting dose difference maps for biochemical failure are shown around the prostate (part a) and the rectum (part b). Coloured contours indicate P values obtained by voxel-by-voxel t testing. Statistically significant differences in dose were seen at points selected to represent obturatorial (part a) and presacral (part b) regions. Adapted with permission from ref.
129
www.nature.com/nrurol with either rectangular (n = 79) or conformal fields (n = 85) to a dose of 66 Gy (ref. 54 ). Significantly fewer clinical failures were noted in those patients treated with rectangular fields than in those treated conformally (9 versus 24; P = 0.012). Dose distributions between the two arms were also compared. In the rectangular arm, a higher dose was delivered to the periprostatic tissues and the obturatorial and presacral regions 54 , areas similar to those identified by Witte and colleagues 129 , and supporting the hypothesis that incidental dose variations in extraprostatic regions might be related to disease recurrence in patients with high-risk disease. The progression of microscopic disease in these regions could, therefore, be prevented by the limited prophylactic irradiation of selected lymph node areas and/or local periprostatic regions. Further studies looking to better define extraprostatic dose-response relationships and clearly establish which elective areas should be targeted are now required.
Toxicity. Treatment-related morbidity is an important factor to consider when selecting patients for elective prophylactic nodal irradiation. In prostate radiotherapy, image-based data mining and the creation of multiple dose maps is an effective means of comparing the spatial distribution of dose between patients with and without toxicity. A second study by Heemsbergen et al. 131 evaluated the radiotherapy plans of 557 men with prostate cancer who had received either 68 Gy or 78 Gy to the prostate as part of a dose escalation trial 14 . Specific anatomical points on the bladder wall for each patient were mapped onto a common reference frame based on distance from the prostate and the angle relative to its centre. Average dose maps were then constructed for patients with and without urinary obstruction. Those patients who experienced urinary obstruction within 2 years were shown to have received a higher dose to the bladder trigone region than patients who did not 131 . A separate study by Palorini et al. 132 used a similar technique to perform a pixel-by-pixel-based analysis of bladder surface maps in men with prostate cancer. The same group then went on to apply this technique to the radiotherapy plans of 539 patients with prostate cancer and analysed the data with respect to end points of acute urinary toxicity and short-term international Prostate Symptom Scores (IPSS) 133 . Dose surface map-based predictors for patients with and without the end points were compared using a two-sided t test and ROC analysis. Across the whole population, a higher dose to the trigone was significantly associated with IPSS increases of ≥10 (area under the curve (AUC) = 0.64; P < 0.001) and ≥15 (AUC = 0.74; P < 0.001) over the course of radiotherapy 133 .
Other data-mining studies have correlated late gastrointestinal toxicity end points with spatial 3D dose distributions. Hoogeman et al. 134 described a method for creating dose surface maps of the anorectum by virtually unfolding the contoured rectal wall and projecting the dosimetry onto a 2D map. They then used this technique to construct relative anorectal maps of 197 men with prostate cancer who had accurate gastrointestinal toxicity data available from trial questionnaires 135 . The study showed that symptoms of faecal incontinence and urgency correlated with higher doses to the lower rectum and anal canal, whereas rectal bleeding was related to dose to the upper rectum 135 . Using a non-rigid registration approach, Acosta et al. 136 evaluated more specific subregions within the rectum, showing that the dose to an area of the anterior rectal wall was significantly correlated with rectal bleeding. This region, which represented <10% of the whole rectal volume, was shown to receive an average of 6 Gy more in patients who experienced bleeding than in those who did not (P < 0.01).
Although thought-provoking, toxicity results from data-mining studies do need to be interpreted with caution. Most are yet to be validated and care is required when considering cause and effect. Anatomical regions can be identified that correlate with toxicity, but radiation doses to these areas are not necessarily responsible for the resulting effects. As with subclinical disease localization, the dose mapping approach formulates exploratory hypotheses regarding dose-toxicity relationships. Making these clinically relevant requires validation in large-scale patient cohorts with multivariate analysis to account for patient-specific confounding factors. This approach would then raise the possibility of translating the findings into practical dose constraints with the potential to improve the therapeutic ratio in WPRT for prostate cancer.
Limitations of image-based data mining
Permutation testing. The appeal of image-based data mining in radiotherapy lies in its ability to spatially localize regions of interest displaying possible doseeffect relationships. However, voxel-by-voxel analysis is subject to the multiple comparisons problem, whereby the simultaneous testing of a large number of voxels can lead to the incorrect rejection of the null hypothesis 126 . These false-positive results have the potential to erroneously infer the presence of an area showing a significant dose-response relationship. Permutation testing has been described as a means of correcting for the multiple comparisons problem in image-based data mining 126 . The technique is based on the premise that, for a given image-based statistical map, the labelling of the images with a particular clinical end point (such as treatment failure or no failure) would be indiscriminate under the null hypothesis -that is, the map would look the same regardless of the label. Evidence against the null hypothesis is then obtained by acquiring a test statistic defined as the maximum value of a normalized dose-difference map (T max ). Unlike voxel-based analysis, T max generates a single figure summarizing the differences in dose distribution between the two image sets, rather than analysing the discrepancy occurring at each individual voxel 126 . A permutation procedure is performed that generates random samples under the null hypothesis, enabling the distribution of T max to be determined. An adjusted P value is then calculated from this distribution. Thus, instead of a P value being created for each voxel, permutation testing gives an overall P value describing the dose difference between the two image sets, thereby accounting for the multiple comparisons problem. Chen et al. 126 applied permutation testing to the data published in the prostate dose-mapping study by Witte and colleagues 129 International Prostate Symptom Score A validated self-assessment tool developed to measure lower urinary tract symptoms and health-related quality of life in patients with prostate disease.
NATuRe RevIeWS | UROlOGy and confirmed the significant difference in dose to the obturator region between patients who experienced treatment failure and those who did not.
Confounding variables.
Dealing with confounding variables is an important issue in image-based data mining. Clinical factors such as tumour size or patient BMI can be associated with both clinical outcome and the dose to a mapped location, potentially resulting in the erroneous inference of a dose-effect relationship 129 . In the study by Witte and colleagues 129 , for an anterior region near the pubic bone, higher doses of >7 Gy were seen in patients with treatment failure than in those without failure (P < 0.01), suggesting an inverted dose response. However, this result can be attributed to an artefact of the dose-mapping procedure with respect to prostate size. In a point within this region at a specified distance from the delineated rectum, patients with a larger prostate receive a higher dose than those with a smaller prostate owing to the increased size of the anteroposterior field 129 . Simultaneously, prostate size was shown to be negatively correlated with outcome -75% of patients with a prostate volume >60 ml experienced disease recurrence within 4 years compared with only 28% of those with a volume <60 ml (ref.
129 ). Prostate size was, therefore, considered to be a confounding factor, generating a false inverted dose-response relationship. Thus, potential confounding factors in data-mining studies must be actively identified from the outset and planned multivariate analyses for each factor must be performed.
Current studies
Two major large-scale randomized controlled trials are currently evaluating the benefit of WPRT in patients with intermediate-risk and high-risk prostate cancer: RTOG 0924 (ref.
137 ) (NCT01368588) and the UKbased PIVOTALboost study 138 (ISRCTN80146950). RTOG 0924 opened to recruitment in 2011, whereas PIVOTALboost only opened in 2017, meaning that informative long-term outcomes from these trials will not be available for at least another 5-10 years. In the interim, the described data-mining studies in prostate cancer have generated interesting hypotheses relating to potential high-risk sites of microscopic disease and OAR regions vulnerable to toxicity. To date, these studies have looked at relatively small patient numbers and require validation. In order to address this, a big-data, image-based mining study is currently underway at our centre, to correlate incidental lymph node dose with clinical outcome using an archive of over 1,000 patients with high-risk prostate cancer treated using a variety of radiotherapy techniques, dose prescriptions and fractionations. The ultimate aim is the definition of a unique statistical atlas of LNI in high-risk disease and the development and validation of a model able to accurately predict those nodal regions most likely to contain micrometastases and, therefore, to be potential targets for selective irradiation.
Conclusions
WPRT in high-risk prostate cancer has long been controversial owing to mixed retrospective evidence and negative prospective randomized trials. However, the negative results from prospective trials should be interpreted with caution owing to insufficient prostate radiation doses, inclusion of low-risk patients less likely to have subclinical pelvic node disease, and suboptimal field size definition. With the advent of increasingly conformal radiotherapy techniques and new data emerging in support of WPRT, the role of pelvic radio therapy should be revisited in the modern IMRT era. New imag ing modalities able to visualize micrometastatic disease, such as PSMA-PET and MRL, have the potential to substantially improve patient selection. Through improved image registration, such imaging can also be used to facilitate the precise delineation of minimally involved lymph nodes to which highdose radiotherapy can now be delivered. When used in conjunction with appropriate image guidance and advanced radiotherapy techniques, radiation dose to the pelvic lymph nodes can now be escalated to up to 60 Gy, thereby facilitating a curative approach to minimally positive lymph node disease. Finally, with modern mapping studies showing a high proportion of patients with microscopic disease in nodal basins outside of the current standard elective WPRT volume, we face a new conundrum as to the most appropriate nodal CTV. Results from large-scale image-based data-mining studies raise the possibility of selective irradiation of specific high-risk nodal groups. When used in conjunction with dose escalation to minimally involved positive nodes, this approach has the potential to increase the therapeutic ratio of pelvic radiotherapy in patients with high-risk prostate cancer and, ultimately, to improve outcomes in this poor prognostic group. Concurrently, the results of RTOG 0924 (ref.
137
) and the UK PIVOTALboost study 138 -ongoing prospective rando mized phase III trials assessing WPRT in the modern radiotherapy era -are eagerly awaited.
